What question did this study set out to answer?

The research seeks to improve KRAS-targeted therapies by integrating various biological contexts to predict outcomes.

April 19, 2026npj Precision Oncology0 citationsOpen Access

Context defines precision: rethinking KRAS inhibition in oncology

SMSerena MarchiòCandiolo Cancer Institute

Key Points

The research seeks to improve KRAS-targeted therapies by integrating various biological contexts to predict outcomes.
Introduces a multidimensional framework for KRAS therapy assessment.
Integrates KRAS mutational status with tumor tissue and immune context.
Suggests aligning trial designs with specific co-mutations and signaling pathways.
Highlights variability in clinical responses across different tumor types based on mutation status.
Proposes that context, rather than mutation alone, is crucial for predicting therapeutic effectiveness.

Abstract

The recent breakthroughs in KRAS inhibition have converted a previously “undruggable” oncogene into a viable therapeutic target. However, the inconsistency in clinical responses across tumor types highlights that mutation alone is not sufficient to predict therapeutic outcomes. This Perspective introduces a multidimensional framework that uniquely integrates KRAS mutational status with tissue, co-mutation, signaling, and immune context to inform rational trial design, predictive biomarker development, and the advancement of KRAS-targeted therapies.

Ask AI

Helpful

Bookmark

View Full Paper